Apexcella Biomedical Inc.
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
Apexcella Biomedical Inc. utilizes its proprietary ApexNK® cell culture platform, cryopreservation technology, and super-donor screening technology to develop autologous and allogeneic ApexNK® therapies, as well as a variety of CAR-NK immunotherapies. The company is committed to providing next-generation, innovative, low-side-effect, and widely applicable cell therapies for multiple types of cancer, striving to develop a diverse range of targeted cancer cell therapy solutions.
The content above was translated by Ai
Founded Year
2022
Unified Business No.
90329217
Status
Active
Number of Employees
0
Total Paid-in
Capital
2,960,917 (NT$)
Location of Company
Taiwan
, Taipei City
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Apexcella Biomedical Inc. is a startup company focusing on cell therapy, founded by Director John Yu, a pioneering scholar in domestic stem cell research and Director of the Institute of Stem Cell and Translational Cancer Research at Chang Gung Memorial Hospital. Through its unique apexNK cell culture technology platform and other technologies, the company is committed to developing autologous and allogeneic apexNK, as well as multiple CAR-NK immune cell therapies, to provide next-generation, innovative, low-side-effect, and broadly applicable cell therapies suitable for a variety of different cancers.
The content above was translated by Ai
